{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T11:57:59Z","timestamp":1756382279756,"version":"3.41.2"},"reference-count":0,"publisher":"AVES YAYINCILIK A.\u015e.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["EJR"],"abstract":"<jats:p>Objective: To retrospectively evaluate the effect of anti-tumor necrosis factor-alpha (TNF-\u03b1) drugs\u00a0on hepatic and renal functions in patients with ankylosing spondylitis (AS).\n\nMethods: A total of 148 patients (89 male, 59 female) who were followed up for a minimum duration\u00a0of 1 year on newly started anti TNF-\u03b1 therapy were included. Patients were divided into 5 groups\u00a0based on the TNF-\u03b1 treatment received. Initially, pre-treatment BASDAI (Bath Ankylosing Spondylitis\u00a0Disease Activity) scores and laboratory results were compared between the groups before the treatment.\u00a0Also, ESR (erythrocyte sedimentation rate), C-reactive protein (CRP), aspartate aminotransferase\u00a0(AST), alanine aminotransferase (ALT), urea, and creatinine values were compared before treatment\u00a0and at 3, 6, and 12 months after treatment. Also presence of hematuria and proteinuria was examined.\n\nResults: Of the overall group, 68 (45%), 33 (22%), 23 (15%), 18 (12%), and 6 (4%) received golimumab,\u00a0certolizumab, etanercept, adalimumab, and infliximab. Baseline demographic characteristics, disease\u00a0activity scores, and laboratory parameters were comparable between the groups (P &gt; .05). There was a\u00a0significant decline in BASDAI scores from baseline at 12 months (pre-treatment 5.24 \u00b1 0.5, 3.01 \u00b1 0.48\u00a0post-treatment at 12 months, P &lt; .001). Although there was an increase in AST and ALT from baseline\u00a0to 3, 6, and 12 months of treatment, the values remained within normal range (P &gt; .05). Also, there\u00a0were no significant changes in mean creatinine levels (P &gt; .05). There were no correlations between\u00a0disease activity parameters (ESR, CRP, and BASDAI) and hepatic and renal functions (P &gt; .05).\n\nConclusion: No hepatotoxicity or nephrotoxicity were found in association with the use of anti-TNF-\u03b1\u00a0agents over a 1 year period. However, hepatotoxicity and nephrotoxicity are among known adverse\u00a0effects of these agents. Based on the existing literature data, routine monitoring of patients in terms\u00a0of potential hepatic and renal toxicity before and after treatment remains a valid recommendation\u00a0in clinical practice.\n\nCite this article as: Akyol L, Balc\u0131 MA. Influence of anti-TNF-\u03b1 treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study. Eur J Rheumatol. 2021;9(1):31-35\n<\/jats:p>","DOI":"10.5152\/eurjrheum.2021.20230","type":"journal-article","created":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T09:43:53Z","timestamp":1622713433000},"page":"31-35","source":"Crossref","is-referenced-by-count":3,"title":["Influence of anti-TNF-\u03b1 treatment on liver and kidney functions in patients with ankylosing spondylitis: A retrospective longitudinal study"],"prefix":"10.5152","volume":"9","author":[{"given":"L\u00fctfi","family":"Akyol","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehmet Ali","family":"Balc\u0131","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3111","published-online":{"date-parts":[[2022,1,1]]},"container-title":["European Journal of Rheumatology"],"original-title":[],"link":[{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/download\/507\/507","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T07:11:45Z","timestamp":1753773105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurjrheumatol.org\/index.php\/pub\/article\/view\/507"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":0,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1,11]]}},"URL":"https:\/\/doi.org\/10.5152\/eurjrheum.2021.20230","relation":{},"ISSN":["2148-4279"],"issn-type":[{"type":"electronic","value":"2148-4279"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}